Further, activation of the AKT/mTOR pathway is observed in metastatic tumors [30,31,32], and increased phosphorylation of AKT, mTOR, and HER2 correlate with poor outcome for disease-free survival [33]. Here, ERBB2 is linked to metastatic neoplasm.